One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Activated PI3K Delta Syndrome. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Joenja lower doses for Activated PI3K delta syndrome (APDS), children 4 and older weighing 13 to 27kg by January 30, 2027, under an sNDA from Pharming Group.
What the FDA is deciding on Joenja lower doses for Activated PI3K Delta Syndrome
The FDA is reviewing Pharming Group's request to update the label of Joenja lower doses (leniolisib) for activated PI3K delta syndrome (APDS), children 4 and older weighing 13 to 27kg.
Follow-on filing to expand Joenja's September 2026 pediatric approval (ages 4-11, at least 27kg) down to children weighing as little as 13kg, using weight-based dosing. Supported by an open-label, multinational, single-arm Phase 3 study showing improvements in lymphadenopathy and naive B cell counts. Priority review.
Who the Joenja lower doses decision matters to
Activated PI3K delta syndrome (APDS) is a rare inherited immune disorder in which an overactive enzyme keeps immune cells from working properly, causing repeated sinus and lung infections, swollen lymph nodes and a higher risk of lymphoma.
Prevalence: About 1 to 2 people per million worldwide (Pharming, citing a 2023 estimate); MedlinePlus Genetics notes the exact number is unknown. See our full Activated PI3K Delta Syndrome page for current treatments, recruiting trials, and community resources.
How Joenja lower doses works
Joenja lower doses: oral inhibitor of PI3K-delta, the immune cell enzyme that is overactive in activated PI3K delta syndrome. Our full Joenja lower doses profile covers how it works, side effects in plain language, and its trial history.
What an approval or a rejection of Joenja lower doses would mean
Joenja is already sold in the US for Activated PI3K Delta Syndrome, so an approval changes its label rather than whether families can get it.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Activated PI3K Delta Syndrome treatment stands today
Read our full Activated PI3K Delta Syndrome treatment summary
Few APDS trials are open. As of October 2026, ClinicalTrials.gov lists no recruiting treatment trials for APDS. Pharming's Joenja studies in children aged 4 to 11 (NCT05438407) and 1 to 6 (NCT05693129) are active but no longer recruiting.
A separate biomarker study (NCT06694363) is recruiting. The FDA is reviewing lower Joenja doses for children 4 to 11 who weigh 13 to 27kg, with a decision due January 30, 2027.
Trials and Joenja both need a confirmed PIK3CD or PIK3R1 variant, so genetic testing is the first step if APDS is suspected. The Immune Deficiency Foundation can help find an immunologist experienced with APDS.
The Activated PI3K Delta Syndrome page has every treatment and trial →Meanwhile, 2 Activated PI3K Delta Syndrome studies are recruiting or not yet recruiting
Whatever the FDA decides here, research on Activated PI3K Delta Syndrome does not stop. None of them test a treatment; they follow patients over time. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Activated PI3K Delta Syndrome. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
One email the day each decision on our calendar is announced, for any condition. No trial alerts and no condition to pick.
We never share your email. Stop anytime from the link in every email. Privacy policy
Frequently asked questions
When will the FDA decide on Joenja lower doses?
The FDA's target date (PDUFA date) for Joenja lower doses in Activated PI3K delta syndrome (APDS), children 4 and older weighing 13 to 27kg is January 30, 2027.
Who disclosed it: Pharming Group. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Pharming press release
What is Joenja lower doses being reviewed for?
Pharming Group submitted an sNDA for Joenja lower doses in Activated PI3K delta syndrome (APDS), children 4 and older weighing 13 to 27kg.
What to know: Follow-on filing to expand Joenja's September 2026 pediatric approval (ages 4-11, at least 27kg) down to children weighing as little as 13kg, using weight-based dosing. Supported by an open-label, multinational, single-arm Phase 3 study showing improvements in lymphadenopathy and naive B cell counts. Priority review.
How it works: Oral inhibitor of PI3K-delta, the immune cell enzyme that is overactive in activated PI3K delta syndrome.
More: the Joenja lower doses drug page explains it in plain language.
Is there already an FDA-approved treatment for Activated PI3K Delta Syndrome?
Yes. Trial Friend's drug list includes 1 FDA-approved drug for Activated PI3K Delta Syndrome.
Approved: Joenja (leniolisib).
Check: the Activated PI3K Delta Syndrome page also searches FDA drug labels for approved treatments.
What did the Joenja lower doses trials show?
In a 12-week randomized, placebo-controlled trial (NCT02435173) of 31 people 12 and older (21 on Joenja, 10 on placebo), the size of the largest lymph nodes shrank more on Joenja (a log-scale change of 0.27 against 0.02), and naive B cells rose 37.4 percentage points against 0.1. The pediatric approval rests on a study of 8 children aged 4 to 11 (NCT05438407) that looked at safety and drug levels.
More: the Joenja lower doses drug page has the full trial history and sources.
What are the side effects of Joenja lower doses?
Joenja has no boxed warning. It may harm an unborn baby, so a pregnancy check is done before starting and effective birth control is used until 1 week after the last dose.
Most common: Headache (24% against 20% on placebo), Sinusitis (19% against 0%), Eczema (14% against 0%), Fast heartbeat (10% against 0%), Diarrhea, fever, back pain, neck pain and hair loss (10% each against 0%), In children 4 to 11: belly pain, cough and respiratory infection.
More: the Joenja lower doses drug page has the label's warnings in full.
Can I get Joenja lower doses before the FDA decides?
Joenja is already FDA approved for Activated PI3K Delta Syndrome. This decision is about a change to its label. Ask your doctor whether the current label already covers you.
Trials: 2 Activated PI3K Delta Syndrome studies are recruiting or not yet recruiting, 0 of them testing a treatment. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Pharming Group directly. Registered programs are listed on ClinicalTrials.gov.
How much will Joenja lower doses cost?
Joenja is already sold in the US for Activated PI3K Delta Syndrome. Trial Friend does not list a price, and what you pay depends on your insurer and drugmaker help.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Joenja lower doses decision?
This page updates with the outcome the day it is announced.
If approved: the label changes. Joenja is already sold in the US for this condition, so there is no new launch to wait for.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Pharming press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.